Loading stock data…
LONN.SW
CHF 491.20+11.40 (+2.38%)
Market OpenUpdated 10:10 AM EDT
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lonza Group AG in the Healthcare sector is trading at $489.30. The stock is currently 19% below its 52-week high of $605.20, remaining 9.1% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why LONN.SW maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current PriceCHF 491.20
Potential Downside
47.5%
Whystock Fair ValueCHF 257.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Buy
Mean targetCHF 673.61+37.1%
RangeCHF 550.00 – CHF 815.00
Fundamentals
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
CHF 34.79B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.29
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Strong income play. Yield provides a meaningful total return floor.
98.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.48%
Volume
Today's trading volume
79,933
Recent News
Is Lonza Group (SWX:LONN) Pricing Too High After Recent Share Price Swings?
Wondering whether Lonza Group at about CHF 508 per share still makes sense for your portfolio, or if better value is available elsewhere? The stock has been fairly volatile recently, with a 4.8% decline over the last week, an 8.7% gain over the last month, and returns of 5.1% lower year to date and 8.9% lower over the last year. Recent coverage has focused on how Lonza Group fits into the wider life sciences sector and what that might mean for investor sentiment. This news context helps...
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
Lonza Group AG's (VTX:LONN) Intrinsic Value Is Potentially 26% Below Its Share Price
Key Insights Lonza Group's estimated fair value is CHF412 based on 2 Stage Free Cash Flow to Equity Lonza Group is...
Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum?
Most readers would already be aware that Lonza Group's (VTX:LONN) stock increased significantly by 8.8% over the past...
Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site
Investing.com - Shares of Lonza spiked in early European trading on Thursday after the Swiss contract pharmaceutical firm confirmed a "significant" long-term commercial supply agreement at one of the world’s largest manufacturing sites for biologic drugs in the United States.